ALZpath, Inc., a developer of diagnostic tools for Alzheimer’s disease and related dementias, has signed a licensing agreement with Siemens Healthineers to broaden global access to blood-based diagnostic testing for Alzheimer’s disease.
Under the agreement, Siemens Healthineers will use ALZpath’s proprietary pTau217 antibody in developing a pTau217 assay to be included in its expanding menu of in vitro diagnostic (IVD) tests for Alzheimer’s disease on its Atellica immunoassay systems.
The licensed pTau217 antibody enables sensitive and accurate detection of Alzheimer’s disease pathology using a simple blood draw, with performance comparable to PET imaging and cerebrospinal fluid (CSF) testing. It is backed by clinical evidence from more than 90 peer-reviewed studies and supports deployment in a wide range of clinical settings through IVD tests.
Siemens Healthineers’ immunoassay and clinical chemistry analyzers are used in clinical laboratories of varying sizes worldwide. Its Atellica systems are engineered for high precision and throughput, facilitating faster processing of test results for patients.
The ALZpath proprietary pTau217 antibody is a key component of some of the most advanced and widely available blood-based Alzheimer’s tests and is already being expanded through licensing agreements with major diagnostics and life sciences companies. ALZpath’s collaborations include firms such as Roche, Beckman Coulter, Bio-Techne, Alamar Biosciences and Quanterix, and partnerships with laboratories like Neurocode, helping extend access to early detection tools worldwide.
The agreement with Siemens Healthineers comes as the need for scalable, accessible diagnostic tools increases, particularly as disease-modifying Alzheimer’s therapies reach broader clinical use and demand grows for earlier patient identification.
